By Roshan Fernandez
Cassava Sciences said its chief medical officer, Dr. James Kupiec, is retiring, effective May 9.
Under Kupiec, the clinical-stage biotechnology company completed a clinical trial program in Alzheimer's disease drug development. Kupiec has been chief medical officer since December 2022 following a stint as Cassava's chief clinical development officer. He previously worked at Pfizer.
Cassava on Monday also said it appointed Jack Moore as senior vice president of clinical development. Moore was most recently the head of global medical affairs at Alector, and also worked at Janssen Pharmaceutica, Novartis Pharmaceuticals, and Celgene.
Write to Roshan Fernandez at roshan.fernandez@wsj.com
(END) Dow Jones Newswires
April 21, 2025 17:17 ET (21:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.